DiaCarta

Founded in 2007, DiaCarta L.L.C. is a translational genomics company dedicated to advancing commercial bio-physical research and development. The company's mission is to revolutionize precision medicine through innovative genomic testing solutions. DiaCarta offers a range of products and services, including cancer progression and therapy response monitoring, colorectal and bladder cancer tests, urinary tract infection detection, in vitro fertilization genetic testing, and infectious disease diagnostics. Their market focus spans clinical laboratories, healthcare providers, and research institutions.

Notable figures associated with DiaCarta include its leadership team and advisors who bring extensive expertise in genomics and biotechnology. The company has attracted significant investment from key industry players, bolstering its research capabilities. DiaCarta's achievements include the development of proprietary technologies like XNA and isobDNA™, which enhance the accuracy and reliability of their diagnostic tests. Their impact is evident in the improved diagnostic precision and patient outcomes in oncology and other medical fields.